文献速递脑血管病

轻型缺血性卒中伴血管闭塞:成功再通与功能结局的关联

Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial.
PubMed 文献 · Stroke · 2026-06-19

该研究为TEMPO-2试验的二次观察性队列分析,纳入517例轻型卒中(NIHSS≤5)伴颅内闭塞患者,随机后4-8小时行CTA评估再通。成功再通(rAOL≥2b/3)占34.6%,与90天恢复至基线功能显著相关(aRR 1.21,95%CI 1.07-1.34),且卒中进展率显著更低(2.8% vs 13.1%,aRR 0.21,95%CI 0.08-0.52)。替奈普酶治疗是成功再通的最强独立预测因素(OR 3.48,95%CI 2.33-5.18)。

要点

  • 成功再通与90天功能恢复至基线显著相关(aRR 1.21)。
  • 成功再通者卒中进展率显著低于未再通者(2.8% vs 13.1%)。
  • 替奈普酶治疗是成功再通的最强独立预测因素(OR 3.48)。

核心结论

  • 成功再通是轻型卒中伴颅内闭塞患者早期及90天功能恢复的关键决定因素,且不依赖于治疗方式。

研究设计与样本

  • TEMPO-2随机对照试验的二次观察性队列分析,纳入886例中517例(58.3%)有随访CTA的患者。

主要发现

  • 成功再通178例(34.6%),未成功再通336例(65.4%)。
  • 成功再通与主要结局显著相关(aRR 1.21,95%CI 1.07-1.34)。
  • 成功再通者卒中进展率2.8%,未再通者13.1%(aRR 0.21,95%CI 0.08-0.52)。
  • 替奈普酶治疗是成功再通的最强独立预测因素(OR 3.48,95%CI 2.33-5.18)。

关键数值与推荐

  • 成功再通定义为改良动脉闭塞病变(rAOL)评分≥2b/3。
  • 主要结局为90天改良Rankin量表评分恢复至基线功能。
  • 卒中进展定义为NIHSS评分恶化≥2分。

临床怎么用

  • 对轻型卒中伴颅内闭塞患者,应关注再通状态以预测功能恢复和卒中进展风险。
  • 替奈普酶治疗可显著提高成功再通几率,支持其在此类患者中的应用。

局限性

  • 为二次观察性队列分析,非随机比较再通状态。
  • 仅58.3%的入组患者有随访CTA,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complete recanalization of cerebral arteries is strongly associated with good functional outcome in ischemic stroke. We hypothesize that successful recanalization results in better functional outcomes. METHODS: This is a secondary observational cohort analysis of TEMPO-2 (Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion), a randomized controlled trial comparing tenecteplase with standard of care (control) in minor stroke (National Institutes of Health Stroke Scale score ≤5) with intracranial occlusion/focal perfusion abnormality ≤12 hours of onset. Among those enrolled based on computed tomography angiography with visible occlusion, a follow-up computed tomography angiography was done at 4 to 8 hours after randomization. The primary outcome was return to baseline functional outcomes using the modified Rankin Scale score at 90 days. Safety outcomes included stroke progression (National Institutes of Health Stroke Scale score ≥2 worsening), bleeding events, and mortality. Patients with successful recanalization, defined as revised Arterial Occlusive Lesion score ≥2b/3, were compared with those with unsuccessful recanalization on follow-up computed tomography angiography. Regression analysis was used to assess the association of successful recanalization with outcomes after adjusting for age, sex, baseline stroke severity, and onset-to-randomization time. RESULTS: Of the 886 enrolled patients, 517 (58.3%) with follow-up computed tomography angiography were included. Of these, 178 (34.6%) had successful recanalization (122 [68.5%]: tenecteplase, 56 (31.5%): control), and 336 (65.4%) did not achieve successful recanalization (unsuccessful recanalization; 134: tenecteplase, 202: control). Baseline characteristics were similar between patients with and without successful recanalization. Successful recanalization was significantly associated with the primary outcome as compared with unsuccessful recanalization (adjusted risk ratio, 1.21 [95% CI, 1.07-1.34]). Patients with successful recanalization had significantly lower rates of stroke progression as compared with unsuccessful recanalization (2.8% versus 13.1%, adjusted risk ratio, 0.21 [95% CI, 0.08-0.52]). Multivariable analysis showed that tenecteplase treatment was the strongest independent predictor of successful recanalization (odds ratio, 3.48 [95% CI, 2.33-5.18]). CONCLUSIONS: Successful recanalization is a critical determinant of early and 90-day functional recovery in patients with minor stroke with intracranial occlusion, regardless of treatment modality. Tenecteplase significantly increases the odds of achieving successful recanalization compared with standard care. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02398656.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Singh N, Strbian D, Vatanpour S, et al. Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial. Stroke. 2026. PMID: 42318629. doi:10.1161/STROKEAHA.125.052872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。